STAAR Surgical Company (STAA) — ESG & Values Scores

Environment story

STAAR Surgical operates a medical device manufacturing business with limited disclosed direct environmental impact. The company expanded manufacturing capacity in Switzerland during fiscal 2025, which introduced multi-site operational costs and elevated inventory levels. No formal net-zero target, Scope 1/2/3 emissions disclosure, or renewable energy percentage has been disclosed in available filings. The company has not published a sustainability report or carbon footprint analysis. Without verified emissions data, decarbonization commitments, or environmental controversies on record, the environmental score reflects baseline uncertainty rather than demonstrated performance.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Switzerland Manufacturing Expansion

STAAR expanded manufacturing capabilities in Nidau, Switzerland facility during fiscal 2025 to supplement U.S. capacity and reduce tariff exposure.

Multi-site operations increase near-term costs and inventory levels; long-term operational efficiency gains dependent on revenue growth alignment.

Social story

STAAR Surgical has disclosed limited social metrics in its 10-K filing. The company underwent significant workforce restructuring in fiscal 2025, recognizing $12.4 million in severance and reduction-in-force costs as part of leadership realignment and cost reduction initiatives. CEO-to-worker pay ratio, detailed diversity metrics, union standing, and supply-chain labor audits are not disclosed in the available filing. The company manufactures medical devices (implantable lenses) with no disclosed material supply-chain labor risks (no cobalt, lithium, or conflict minerals involvement). Absence of documented labor disputes, strikes, or NLRB complaints on record mitigates social risk, but lack of transparency on workforce composition and compensation equity limits full assessment.

Criticisms on file

No material criticisms on file for this pillar.

Disclosed initiatives

Leadership Realignment and Cost Optimization

In first half of 2025, STAAR restructured leadership team, realigned organizational structure, and reduced workforce by $12.4 million in severance costs.

Workforce reduction may affect employee morale and institutional knowledge; cost savings support near-term operational efficiency.
EVO Experience Center

STAAR operates hands-on training and education facility at Lake Forest, California headquarters for surgeon training on ICL procedures.

Educational initiative supports workforce development in customer (surgeon) base; reflects commitment to medical professional training.

Governance story

STAAR Surgical experienced significant governance disruption in fiscal 2025. The company announced a merger agreement with Alcon in August 2025, followed by stockholder rejection of the merger at a special meeting on January 6, 2026, resulting in $17.1 million in merger-related professional fees and a subsequent Cooperation Agreement with Broadwood Partners (largest shareholder). This agreement included $7.0 million in reimbursement to Broadwood for engagement expenses and committed certain governance and leadership changes. The merger termination and activist involvement signal governance volatility. Board independence percentage, share structure details, and annual lobbying expenditures are not disclosed in the 10-K. No antitrust, consumer-safety, privacy, or financial-fraud regulatory proceedings are mentioned. Absence of disclosed dual-class voting rights or active deregulatory lobbying mitigates governance risk.

Criticisms on file

Alcon Merger Termination and Activist Engagement
Source: STAA 10-K, Item 7 MD&A – Termination of Alcon Merger Agreement; Note 19 – Subsequent Events; Cooperation Agreement with Broadwood Partners dated January 14, 2026.

Disclosed initiatives

Cooperation Agreement with Broadwood Partners

Following merger termination on January 6, 2026, STAAR entered into a Cooperation Agreement with Broadwood Partners (largest stockholder) on January 14, 2026, providing for governance and leadership changes and reimbursement of approximately $7.0 million in stockholder expenses.

Agreement reflects activist shareholder influence on governance; may signal improved strategic alignment but introduces uncertainty regarding board composition and decision-making independence.
Merger Process and Stockholder Engagement

STAAR conducted a special stockholder meeting on January 6, 2026, to vote on proposed merger with Alcon; stockholders voted against the transaction by majority.

Demonstrates stockholder governance rights and shareholder voice; merger rejection indicates management proposal faced significant investor opposition.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of STAAR Surgical Company. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open STAAR Surgical Company in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)